| Product Code: ETC12629438 | Publication Date: Apr 2025 | Updated Date: Feb 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
In 2024, Australia`s large molecule drug substance CDMO market witnessed a notable import trend, with a steady increase in the inflow of raw materials and components for pharmaceutical manufacturing. This surge in imports reflects the industry`s reliance on external sources for essential drug substances.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Large Molecules Drug Substance CDMO Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, 2022 & 2032F |
3.3 Australia Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Australia Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2022 & 2032F |
3.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2022 & 2032F |
3.7 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2022 & 2032F |
3.8 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.9 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Australia Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologic drugs in the pharmaceutical industry |
4.2.2 Growing trend towards outsourcing manufacturing activities for large molecules |
4.2.3 Advancements in technology and expertise in large molecule drug substance development |
4.3 Market Restraints |
4.3.1 Stringent regulations and compliance requirements in the biopharmaceutical sector |
4.3.2 High initial investment and infrastructure costs for setting up large molecule manufacturing facilities |
5 Australia Large Molecules Drug Substance CDMO Market Trends |
6 Australia Large Molecules Drug Substance CDMO Market, By Types |
6.1 Australia Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2022 - 2032F |
6.1.3 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2022 - 2032F |
6.1.4 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2022 - 2032F |
6.1.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2022 - 2032F |
6.1.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2022 - 2032F |
6.1.7 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2022 - 2032F |
6.2 Australia Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2022 - 2032F |
6.2.3 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2022 - 2032F |
6.2.4 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2022 - 2032F |
6.2.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2022 - 2032F |
6.2.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2022 - 2032F |
6.3 Australia Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2022 - 2032F |
6.3.3 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2022 - 2032F |
6.3.4 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2022 - 2032F |
6.3.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2022 - 2032F |
6.3.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2022 - 2032F |
6.4 Australia Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2022 - 2032F |
6.4.3 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2022 - 2032F |
6.4.4 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2022 - 2032F |
6.4.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2022 - 2032F |
6.4.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2022 - 2032F |
6.5 Australia Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2022 - 2032F |
6.5.3 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2022 - 2032F |
6.5.4 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2022 - 2032F |
6.5.5 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2022 - 2032F |
6.5.6 Australia Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2022 - 2032F |
7 Australia Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Australia Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Australia Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Australia Large Molecules Drug Substance CDMO Market Key Performance Indicators |
8.1 Capacity utilization rate of large molecule drug substance manufacturing facilities |
8.2 Number of new partnerships and collaborations with pharmaceutical companies |
8.3 Rate of adoption of innovative manufacturing technologies for large molecules |
8.4 Percentage of revenue derived from large molecule drug substance CDMO services |
8.5 Number of new product introductions and successful technology transfers for large molecules |
9 Australia Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Australia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2022 & 2032F |
9.2 Australia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2022 & 2032F |
9.3 Australia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2022 & 2032F |
9.4 Australia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2022 & 2032F |
9.5 Australia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Australia Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Australia Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2025 |
10.2 Australia Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here